Mesenchymal stroma/stem cells: Haematologists’ friend or foe?

Boaz Nachmias, Eran Zimran, Batia Avni

Research output: Contribution to journalReview articlepeer-review

Abstract

Mesenchymal stromal cells (MSCs) are non-haematopoietic cells found in fetal and adult organs, that play important roles in tissue repair, inflammation and immune modulation. MSCs residing in the bone marrow interact closely with haematopoietic cells and comprise an important component of the microenvironment supporting haematopoiesis, in both health and disease states. Since their identification in 1970, basic scientific and preclinical research efforts have shed light on the role of MSCs in the regulation of haematopoiesis and evoked interest in their clinical application in haematopoietic stem cell transplantation (HSCT) and malignant haematology. Over the last two decades, these research efforts have led to numerous clinical trials, which have established the safety of MSC therapy; however, the optimal mode of administration and the benefit remain inconclusive. In this paper, we will review the clinical experience with use of MSCs in HSCT for enhancement of engraftment, prevention and treatment of graft-versus-host disease and haemorrhagic cystitis. Then, we will discuss the contradictory evidence regarding tumour-promoting versus tumour-suppressing effects of MSCs in haematological malignancies, which may have relevance for future clinical applications.

Original languageEnglish
Pages (from-to)175-189
Number of pages15
JournalBritish Journal of Haematology
Volume199
Issue number2
DOIs
StatePublished - Oct 2022
Externally publishedYes

Keywords

  • GVHD
  • engraftment
  • mesenchymal cells
  • tumorigenesis

Fingerprint

Dive into the research topics of 'Mesenchymal stroma/stem cells: Haematologists’ friend or foe?'. Together they form a unique fingerprint.

Cite this